Search

everythinglearnresearchcommunity

for

Search:↓

Red and near-infrared light-emitting fabric may help improve psoriasis, PMLE, and alopecia areata.

Triamcinolone is more effective than methotrexate for treating localized alopecia areata.

Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.

PRP is an effective and safe treatment for hair loss in women.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Intralesional methotrexate effectively treats patchy alopecia areata by reducing inflammation.

The document concludes that various cosmetic and drug treatments are available for hirsutism, and some new drugs show promise.

Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.

Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.

Dermatologists play a key role in identifying and documenting signs of abuse and injury for forensic investigations.

Corticosteroids may not effectively control oxidative stress in alopecia areata, possibly leading to relapses.

Current treatments for Alopecia Areata don't fully meet patients' needs, indicating a need for better therapies.

Successful surgical hair restoration requires careful planning, precise execution, and proper aftercare, using techniques like follicular unit transplantation and correct hair angling for best cosmetic results.

The document concludes that careful planning, efficient use of every hair graft, and setting surgical priorities are crucial for successful hair restoration surgery.

Higher interleukin-15 levels are linked to more severe alopecia areata, but not to age or gender.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

CAH is a genetic disorder affecting cortisol production and causing hormonal imbalances, with treatment and diagnosis varying by form and symptoms.

Some people with severe, long-lasting baldness responded well to a specific combination treatment.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

Baricitinib effectively regrows hair in severe alopecia areata cases.

JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.

Baseline severity and relapse history affect alopecia areata treatment and recurrence.

New treatments for skin conditions show promise, especially Coacillium® for hair growth in young people with alopecia areata.

Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.

Real-life dosing of biologics for plaque psoriasis often deviates from recommended guidelines, especially for high-need patients.

People with alopecia areata have higher levels of osteopontin, which might be important in the disease's development, but this doesn't relate to how severe the disease is.

Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.